Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
$23.01
$22.89
$3.11
$23.21
$389.61M2.111.52 million shsN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$159.28
-0.3%
$159.63
$140.68
$169.99
$382.89B0.477.73 million shs42,953 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$763.05
-3.3%
$849.30
$711.40
$972.53
$728.68B0.343.30 million shs41,588 shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$85.61
-0.9%
$91.18
$81.04
$134.63
$217.41B0.411.10 million shs70,003 shs
Organon & Co. stock logo
OGN
Organon & Co.
$14.04
-2.9%
$15.22
$13.87
$23.10
$3.64B0.762.55 million shs10,588 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.00%0.00%0.00%0.00%0.00%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+2.89%-2.03%-3.37%+10.89%+3.65%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-3.78%-4.08%-13.43%+0.85%+1.59%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.33%-1.46%-6.74%-12.93%-33.55%
Organon & Co. stock logo
OGN
Organon & Co.
-2.19%-1.02%+0.85%-6.63%-19.50%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.7524 of 5 stars
0.00.00.04.70.62.50.0
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.2198 of 5 stars
2.33.04.23.92.62.50.6
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.9186 of 5 stars
3.45.03.34.03.22.51.9
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
5 of 5 stars
4.35.05.03.92.73.33.8
Organon & Co. stock logo
OGN
Organon & Co.
4.7014 of 5 stars
3.21.03.33.72.91.73.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
0.00
N/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.56
Moderate Buy$171.337.57% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$1,009.7232.33% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.65
Moderate Buy$117.1236.80% Upside
Organon & Co. stock logo
OGN
Organon & Co.
2.43
Hold$20.8048.20% Upside

Current Analyst Ratings Breakdown

Latest MRK, LLY, OGN, HARP, and JNJ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/2/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.00
4/2/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/10/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/5/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$159.00 ➝ $171.00
3/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$970.00 ➝ $1,100.00
2/19/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.00
2/18/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$128.00 ➝ $105.00
2/14/2025
Organon & Co. stock logo
OGN
Organon & Co.
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$26.00 ➝ $24.00
2/14/2025
Organon & Co. stock logo
OGN
Organon & Co.
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $16.00
2/12/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$122.00 ➝ $115.00
(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
$37.34M10.43N/AN/A$1.63 per share14.12
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$88.82B4.32$13.09 per share12.17$29.69 per share5.36
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B16.06$12.44 per share61.34$15.05 per share50.70
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$64.17B3.37$2.97 per share28.82$14.85 per share5.77
Organon & Co. stock logo
OGN
Organon & Co.
$6.40B0.57$4.50 per share3.12($0.27) per share-51.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
-$67.73M-$8.76N/AN/AN/A-81.68%-893.55%-45.98%N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$14.07B$6.6523.8914.392.5618.20%34.24%13.63%4/15/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7165.6324.521.4023.51%85.24%16.19%5/1/2025 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$17.12B$6.7312.798.650.7726.67%45.35%17.36%4/24/2025 (Estimated)
Organon & Co. stock logo
OGN
Organon & Co.
$864M$3.334.243.750.9013.49%431.62%8.03%5/1/2025 (Estimated)

Latest MRK, LLY, OGN, HARP, and JNJ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64N/AN/AN/A$12.77 billionN/A
5/1/2025N/A
Organon & Co. stock logo
OGN
Organon & Co.
$0.92N/AN/AN/A$1.53 billionN/A
4/24/2025N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.16N/AN/AN/A$15.59 billionN/A
4/15/2025N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.59N/AN/AN/A$21.65 billionN/A
2/13/2025Q4 2024
Organon & Co. stock logo
OGN
Organon & Co.
$0.92$0.83-$0.09$0.42$1.57 billion$1.59 billion
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
2/4/2025Q4 2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$1.85$1.72-$0.13$1.48$15.51 billion$15.62 billion
1/22/2025Q4 2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$1.99$2.04+$0.05$1.41$22.44 billion$22.52 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
N/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.963.11%+5.43%74.59%63 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.79%+15.21%51.24%11 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.243.78%+5.73%48.14%14 Years
Organon & Co. stock logo
OGN
Organon & Co.
$1.127.98%+25.99%33.63%N/A

Latest MRK, LLY, OGN, HARP, and JNJ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/28/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.813.32%3/17/20253/17/20254/7/2025
2/13/2025
Organon & Co. stock logo
OGN
Organon & Co.
quarterly$0.287.3%2/24/20252/24/20253/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
N/A
1.89
1.89
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.43
1.11
0.86
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.79
1.36
1.15
Organon & Co. stock logo
OGN
Organon & Co.
17.73
1.70
1.21

Institutional Ownership

CompanyInstitutional Ownership
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
74.01%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Organon & Co. stock logo
OGN
Organon & Co.
77.43%
CompanyEmployeesShares OutstandingFree FloatOptionable
Harpoon Therapeutics, Inc. stock logo
HARP
Harpoon Therapeutics
5316.93 million14.05 millionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
152,7002.41 billion2.40 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
69,0002.53 billion2.53 billionOptionable
Organon & Co. stock logo
OGN
Organon & Co.
10,000257.95 million253.93 millionNot Optionable

Recent News About These Companies

Organon acquires rights for Tofidence from Biogen
Organon, Shanghai Henlius Biotech: EMA validates MAA for HLX11

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Harpoon Therapeutics stock logo

Harpoon Therapeutics NASDAQ:HARP

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$158.96 -0.86 (-0.54%)
As of 09:36 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$765.26 -23.83 (-3.02%)
As of 09:36 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$85.45 -0.94 (-1.09%)
As of 09:36 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Organon & Co. stock logo

Organon & Co. NYSE:OGN

$13.97 -0.48 (-3.32%)
As of 09:36 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.